Wilson v. Corning, Inc. — Federal Circuit Affirms Cell Culture Vessel Patents
John R. Wilson asserted three patents covering multilayer cell culture vessel technology against Corning, Inc., targeting product lines including CellSTACK, HYPERFlask, HYPERStack, Multilayer Flask, and RoboFlask. The Federal Circuit affirmed the lower court decision in a 481-day appellate proceeding, leaving Corning’s exposure intact and Wilson’s patent portfolio standing.
Three Cell Culture Patents Survive Federal Circuit Scrutiny Against Corning
John R. Wilson filed Case No. 24-1065 at the Court of Appeals for the Federal Circuit on 18 October 2023, asserting infringement of three US patents — US7745209B2, US8178345B2, and US8273572B2 — all directed to multilayer cell culture vessel technology. The accused products span Corning’s commercial bioprocessing catalogue: CellSTACK, HYPERFlask, HYPERStack, Multilayer Flask, and RoboFlask. Corning, represented by Winston & Strawn LLP, is a leading manufacturer of laboratory and life sciences consumables with substantial market share in cell culture vessel supply.
The Federal Circuit closed the case on 10 February 2025, issuing a terse affirmance: the court ordered and adjudged ‘AFFIRMED,’ signalling that the panel found no reversible error in the disposition below. The basis of termination is recorded as ‘Appeal Dismissed,’ which, read alongside the affirmance verdict, suggests the appeal was resolved on the merits in favour of upholding the lower tribunal’s outcome — leaving Wilson’s patent claims and any findings below undisturbed. Corning retains no further appellate path at this court level.
At 481 days, the proceeding ran longer than many Federal Circuit infringement appeals resolved on the briefs alone, suggesting meaningful substantive briefing and possibly oral argument. The public record does not disclose the specific claim construction disputes or obviousness grounds that Corning may have pressed on appeal, nor whether damages were separately addressed. What the affirmance confirms is that Wilson’s three-patent portfolio covering multilayer cell culture vessel architecture withstood appellate challenge by one of the sector’s most significant commercial players.
Filing to Appeal Dismissed in 481 days
481 days from filing to Federal Circuit decision — above the median for single-appellant Federal Circuit infringement appeals
Federal Circuit affirms: what the ruling means for both parties
Affirmance means the lower decision stands without reversible error
When the Federal Circuit issues an ‘AFFIRMED’ order, it is confirming that the panel reviewed the record and found no reversible legal error in the decision below — whether on claim construction, infringement analysis, or other grounds Corning raised. The standard of review varies by issue (de novo for claim construction, clear error for fact findings), and an affirmance clears all of them. The lower tribunal’s outcome carries full legal force.
Appellate affirmanceWilson’s three-patent portfolio emerges with appellate validation
For John R. Wilson, the Federal Circuit’s affirmance is a significant enforcement milestone. All three patents — US7745209B2, US8178345B2, and US8273572B2 — now carry the weight of appellate validation, strengthening their enforceability against current and future infringers. Any findings of infringement or validity from the lower proceeding are locked in. The patents’ commercial relevance to multilayer cell culture vessels is implicitly confirmed by the affirmance.
Patent enforceability strengthenedCorning exhausts Federal Circuit appeal; en banc or cert remain
For Corning, the affirmance closes the standard appellate path at the Federal Circuit panel level. Remaining options — a petition for en banc rehearing or a certiorari petition to the Supreme Court — face very high bars and are statistically unlikely to succeed absent a circuit-split or constitutional question. Corning’s accused product lines (CellSTACK, HYPERFlask, HYPERStack, Multilayer Flask, RoboFlask) may require design-arounds or licensing consideration.
Appellate options narrowedMultilayer cell culture vessel IP landscape shifts toward Wilson
The affirmance signals to the broader cell culture and bioprocessing sector that Wilson’s multilayer vessel patents are durable against challenge from a well-resourced defendant. Competitors developing or selling products functionally comparable to CellSTACK or HYPERFlask should treat all three patents as actively enforceable. Freedom-to-operate analyses for multilayer cell culture vessel platforms should now account for the elevated validity confidence these patents carry post-affirmance.
Elevated patent risk for sectorFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | John R. Wilson | Individual | Independent inventor and patent holder — holder of US7745209B2, US8178345B2, US8273572B2Search in Eureka ↗ |
| Defendant | Corning, Inc. | Company | Corning, Inc. — global life sciences manufacturer of cell culture vessels and bioprocessing consumablesSearch in Eureka ↗ |
| Plaintiff counsel | Britta Loftus | Attorney | Counsel for John R. WilsonSearch in Eureka ↗ |
| Plaintiff counsel | Devan V. Padmanabhan | Attorney | Counsel for John R. WilsonSearch in Eureka ↗ |
| Plaintiff counsel | Erin Dungan | Attorney | Counsel for John R. WilsonSearch in Eureka ↗ |
| Plaintiff counsel | Mariah L. Reynolds | Attorney | Counsel for John R. WilsonSearch in Eureka ↗ |
| Plaintiff counsel | Michelle Dawson | Attorney | Counsel for John R. WilsonSearch in Eureka ↗ |
| Plaintiff counsel | Paul J. Robbennolt | Attorney | Counsel for John R. WilsonSearch in Eureka ↗ |
| Plaintiff counsel | Sri Sankaran | Attorney | Counsel for John R. WilsonSearch in Eureka ↗ |
| Plaintiff law firm | Padmanabhan & Dawson PLLC | Law Firm | Representing John R. WilsonSearch in Eureka ↗ |
| Defendant counsel | Edward A. Day | Attorney | Counsel for Corning, Inc.Search in Eureka ↗ |
| Defendant counsel | George C. Lombardi | Attorney | Counsel for Corning, Inc.Search in Eureka ↗ |
| Defendant counsel | Ivan Michael Poullaos | Attorney | Counsel for Corning, Inc.Search in Eureka ↗ |
| Defendant counsel | Linda T. Coberly | Attorney | Counsel for Corning, Inc.Search in Eureka ↗ |
| Defendant counsel | Michael A. Meneghini | Attorney | Counsel for Corning, Inc.Search in Eureka ↗ |
| Defendant counsel | Robine K. Morrison | Attorney | Counsel for Corning, Inc.Search in Eureka ↗ |
| Defendant law firm | Winston & Strawn, LLP | Law Firm | Representing Corning, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s order — ‘ORDERED and ADJUDGED: AFFIRMED’ — is a merits disposition confirming that the panel found no reversible error in the lower tribunal’s ruling across all issues presented by Corning. The unadorned affirmance without written opinion (if decided under Rule 36) or with opinion carries equivalent legal effect: the lower decision stands in full. For Wilson, this means the infringement and validity findings below are binding. For Corning, no aspect of the lower ruling was disturbed, and the accused cell culture vessel product lines remain subject to those findings.
US7745209B2, US8178345B2 & US8273572B2 — Multilayer Cell Culture Vessel Technology
The three patents at issue — US7745209B2 (App. No. 11/433859), US8178345B2 (App. No. 12/211378), and US8273572B2 (App. No. 12/783217) — collectively cover multilayer cell culture vessel technology, a platform critical to large-scale mammalian cell culture in biopharmaceutical manufacturing, vaccine production, and research. The sequential application numbers suggest a continuation or continuation-in-part family strategy, with Wilson building claim coverage across vessel design, system configuration, and likely method-of-use claims through multiple prosecution rounds.
Corning’s accused product lines — CellSTACK, HYPERFlask, HYPERStack, Multilayer Flask, and RoboFlask — represent cornerstone products in the global cell culture vessel market, used extensively in biopharmaceutical upstream processing. The fact that Wilson’s patent family could be asserted against this breadth of Corning’s catalogue indicates substantial claim coverage. For competitors including Thermo Fisher, Sartorius, and emerging bioprocessing entrants, the Federal Circuit’s affirmance elevates the IP risk profile of any multilayer vessel product that shares architectural features with the Corning accused products.
Should you run an FTO against US7745209B2, US8178345B2 & US8273572B2?
R&D and product teams developing multilayer cell culture vessels, large-surface-area flask systems, or automated bioprocessing vessel formats should treat this Federal Circuit affirmance as a trigger for formal FTO analysis. The three Wilson patents now carry appellate validation and an elevated validity presumption. Products in the same functional class as CellSTACK, HYPERFlask, HYPERStack, or RoboFlask — whether designed for mammalian cell expansion, viral vector production, or cell therapy manufacturing — fall squarely within the risk perimeter.
PatSnap Eureka’s FTO Search Agent can map the claim boundaries of US7745209B2, US8178345B2, and US8273572B2 against your product specifications, surface prior art that may inform design-around strategies, and flag prosecution history estoppel that constrains Wilson’s claim scope. For legal teams advising bioprocessing clients, Eureka’s litigation history overlay identifies how each patent has performed in adversarial proceedings — giving you the full risk picture before commercial launch or licensing negotiation.
Run a freedom-to-operate analysis on US7745209B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit Cases: Cell Culture & Bioprocessing Patent Appeals
Federal Circuit infringement appeals involving bioprocessing and cell culture vessel patents — cases comparable to Wilson v. Corning on technology, claim type, and appellate posture.
What this case signals for the cell culture vessel IP landscape
An affirmed Federal Circuit ruling on multilayer cell culture vessel patents raises the enforcement bar for the entire bioprocessing consumables sector.
Affirmed patents demand immediate FTO review for cell culture vessel makers
Any company manufacturing or commercialising multilayer cell culture vessels should conduct a fresh FTO analysis against US7745209B2, US8178345B2, and US8273572B2. Federal Circuit affirmance elevates the validity presumption and closes the most accessible challenge route. Products architecturally similar to CellSTACK or HYPERStack carry heightened exposure.
Wilson’s portfolio is now a licensing leverage tool in bioprocessing
Three patents covering distinct aspects of multilayer cell culture vessel technology, validated at the Federal Circuit, give Wilson substantial licensing leverage. Companies in active product development for large-scale mammalian cell culture should model licensing cost scenarios against the alternative of design-around investment — especially given the breadth of Corning products found to be at issue.
Wilson v Corning — key questions answered
The Federal Circuit affirmed the lower court’s decision in favour of plaintiff John R. Wilson, finding no reversible error in the infringement action involving three multilayer cell culture vessel patents (US7745209B2, US8178345B2, US8273572B2) asserted against Corning’s CellSTACK, HYPERFlask, HYPERStack, Multilayer Flask, and RoboFlask product lines. The case closed on 10 February 2025 after 481 days of appellate proceedings.
Wilson asserted US7745209B2 (App. No. 11/433859), US8178345B2 (App. No. 12/211378), and US8273572B2 (App. No. 12/783217). The three patents form a continuation-style family covering multilayer cell culture vessel technology — platforms used in large-scale mammalian cell bioprocessing, biopharmaceutical manufacturing, and research. The sequential application numbers suggest progressively refined claim coverage across the same technical domain.
The affirmance means the lower court’s findings regarding Corning’s accused products — CellSTACK, HYPERFlask, HYPERStack, Multilayer Flask, and RoboFlask — are binding. Corning’s standard appellate path is exhausted at the panel level. The company may seek en banc rehearing or Supreme Court certiorari, but both face very high thresholds. Product design-arounds or licensing discussions with Wilson are likely the most practical commercial responses.
Corning retains theoretical options: a petition for en banc rehearing at the Federal Circuit, or a certiorari petition to the US Supreme Court — both statistically unlikely to succeed absent exceptional legal grounds. Separately, Corning or a third party could file inter partes review petitions at the USPTO challenging the patents’ validity, though the post-affirmance litigation history and any estoppel arising from prior proceedings would complicate that path.
The Federal Circuit affirmance elevates the enforceability and validity confidence of all three Wilson patents. Any manufacturer or developer of multilayer cell culture vessels — particularly formats comparable to CellSTACK, HYPERFlask, or HYPERStack — should conduct or refresh freedom-to-operate analyses against US7745209B2, US8178345B2, and US8273572B2 before product launch or market entry. The affirmed patents now represent a higher-risk IP position than pre-appeal.
PatSnap Eureka searches patents and litigation data to answer instantly.